Having sat in on the Vaccines and Related Biological Products (VRBP) Advisory Committee meetings on December 10th and December 17th, which (respectively) led to FDA granting Emergency Use Authorization (EUA) to both Pfizer/BioNTech and Moderna on December 11th and December 18th, I can tell you that there was a great deal of scientific rigor applied in each of the more than 8.5 hours-long meetings. The question put upon the Advisory Committee was in both cases: Click Here For Complete Article Text
|
|||||||||||||||||||||||||||
| Application Sequencing | |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
| Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||||||||